Kuru

BERWYN, Pa., Sept. 13, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today the publication of three granted US patents – US11400075 (link), US11376238 (link), and US11382893 (link). The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap. They will provide intellectual property protection through 2031, prior to any patent extensions. The patents strengthen and expand the Company's intellectual property portfolio. The Company now has issued patents covering a wide range of neurodegenerative diseases, including Alzheimer's disease (AD), alpha-synucleopathies, such as Parkinson's disease (PD), tauopathies, such as frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE) and acute injuries such as stroke and traumatic brain injury. "These additional patents represent further proof for our platform drug, buntanetap, which acts on a variety of neurodegenerative disorders by inhibiting multiple neurotoxic proteins," said Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis. Summary of key coverage: A method of treating amyloid lateral sclerosis, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of superoxide dismutase protein1 and TDP43. A method of treating Huntington's disease, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of Huntingtin protein. A method of treating prion diseases, a family of ultra-rare progressive neurodegenerative disorders, by administering buntanetap. There is additional coverage of particular Prion diseases, including scrapie prion, transmissible mink encephalopathy (TME), chronic wasting disease (CWD), bovine spongiform encephalopathy (BSE) prion, feline spongiform encephalopathy (FSE), exotic ungulate encephalopathy (EUE), kuru prion, Creutzfeldt-Jakob disease (CJD), Variant Creutzfeldt-Jakob disease (vCJD, nvCJD), Gerst-mann-Straussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI) prion. About Buntanetap Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. In a Phase 2a clinical trial in AD and PD patients, buntanetap was shown to be well-tolerated and safe, and its pharmacokinetics were found to be in line with levels measured earlier in humans, meeting both the primary and secondary endpoints. Additionally, exploratory endpoints were also met, as treatment with buntanetap resulted in statistically significant improvement in motor function in PD patients and cognition in AD patients. Presently buntanetap is being studied in a phase 3 early PD study and will enter a phase 2/3 study in AD patients later in the year. About Annovis Bio, Inc. Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company developing transformative therapies that treat neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD) and other chronic and acute neurodegenerative diseases. The Company believes that it is the only company developing a drug that inhibits more than one neurotoxic protein, improves the information highway of the nerve cell, known as axonal transport, reduces inflammation and protects nerve cells from dying in chronic and acute neurodegeneration. Annovis conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study, buntanetap showed improvements in cognition and memory in AD as well as body and brain function in PD patients. For more information on Annovis Bio, please visit the Company's website and follow us on LinkedIn and Twitter. Forward-Looking Statements Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of buntanetap clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law. Media and Investor Contact: Nic Johnson Russo Partners, LLC (303) 482-6405 nic.johnson@russopartnersllc.com Company Codes: NYSE:ANVS

Maximum Demand for Human Prion Disease Diagnostics to Concentrate in North America with the U.S. at the Forefront Fact.MR’s survey on the human prion disease diagnostic market offers insights into key trends and opportunities affecting growth in the market. It studies scope for expansion across various segments in terms of technology. The report presents analysis of growth drivers, challenges, and recent developments influencing sales of human prion disease diagnostics worldwide. Fact.MR – A Market Research and Competitive Intelligence Provider: Fact.MR’s latest study analyses the growth trajectory of the human prion disease diagnostic market. Human prion diseases (transmissible spongiform encephalopathies, TSEs) are rare, progressive, and fatal neurogenerative diseases caused by the aggregation of misfolded prion protein in neuronal tissue. Because they pose a high risk of transmission, these diseases are under active surveillance in several countries. Thanks to ongoing technological advancements in the healthcare sector, medical professionals are able to develop solutions that facilitate the early diagnosis of such diseases. Considering this, Fact.MR has projected the global human prion diseases diagnostics market to expand at a steady pace over the forecast period 2021-2031. As per the article titled “Infectious Diseases of Poverty” published by the National Centre for Biotechnology Information (NCBI), types of these diseases include Kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome, and fatal familial insomnia. The article states that currently there are no specific therapeutic and prophylactic interventions available for the treatment of human prion diseases. Steady progress in the field of clinical diagnostics and soaring concerns pertaining to causes, symptoms, and types of human prior diseases will create conducive environment for the expansion of the market. Request a report sample to gain comprehensive insights at Several government organizations are providing research and development aids to facilitate the development of treatment options and diagnosis for prion diseases. This is anticipated to offer lucrative opportunities for market players in the forthcoming years. As per Fact.MR, China is expected to emerge as an attractive pocket in the global human prion disease diagnostics market. Increasing adoption of technologically advanced and digital solutions in the healthcare sector is expected to fuel sales of human prion disease diagnostic solutions in China. “Government-backed investment in research of diagnostic methods and drug development in various countries is anticipated to drive the human prion diseases diagnostics market. Besides this, awareness programs launched by non-profit organizations in emerging economies will continue fueling the demand for human prion disease diagnostics over the assessment period," says the Fact.MR analyst. Key Takeaways from Human Prion Disease Diagnostics Market Survey Demand for human prion disease diagnostics is projected to rise in the U.S. owing to the presence of robust healthcare infrastructure. Rising awareness regarding health and wellness and initiatives launched by non-profit to educate common men about types and symptoms of the disease will drive sales in India and China. The U.K. is projected to continue exhibiting high demand for human prion disease diagnostics. Growth in the market will be steered by digitization of medical procedures and diagnostics. Expansion of healthcare sector will support growth in Japan. Growth Drivers: Advancements in magnetic resonance imaging (MRI) procedures and equipment are anticipated to fuel sales of human prion disease diagnostic solutions. Expansion of the life science sector in emerging economies will continue propelling demand for human prion disease diagnostics. To gain in-depth insights on Human Prion Disease Diagnostics Market, request methodology at Competitive Landscape Companies operating in the global human prion disease diagnostic market are actively investing in research and development to develop accurate and easily accessible prion disease diagnostic solutions. Besides this, mergers, acquisitions, and collaborations are expected to assist market players in solidifying growth prospects over the forecast period. For instance, Bio-rad Laboratories has launched its Western Blot Sample Testing for the diagnosis of various human prion diseases. Similarly, Novartis AG and its team of researchers have started combining expertise and cutting-edge technology to develop effective prion disease diagnostic solutions. The products will be ready to be launched in the market soon. Key Players in the Human Prion Disease Diagnostic Market Include: PrioSense Ltd. Bio-Rad Laboratories, Inc. Abbott Diagnostics, Inc. Gradipore Inc. Prionics AG Prion Development Laboratories Beckman Coulter Novartis AG Covance, Inc. Gene Thera, Inc. More Valuable Insights on Human Prion Disease Diagnostic Market Fact.MR provides an unbiased analysis of the human prion disease diagnostic market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global human prion disease diagnostic market with a detailed segmentation on the basis of: Technology: Electroencephalography Magnetic Resonance Imaging Cerebrospinal Fluid Examination Computed Tomography Tonsil Biopsy Brain Biopsy Blood Tests Neurological Examinations Regions: North America Latin America Europe East Asia South Asia Oceania MEA Key Questions Covered in the Human Prion Disease Diagnostic Market Report The report offers insight into human prion disease diagnostic market demand outlook for 2021-2031 The market study also highlights projected sales growth for human prion disease diagnostic market between 2021 and 2031 Human prion disease diagnostic market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry Human prion disease diagnostic market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others Explore Fact.MR’s Coverage on the Healthcare Domain – Rare Neurodegenerative Disease Treatment Market- Market participants are increasing their investments in medication development for the treatment of neurodegenerative diseases, and patients are becoming more aware of the various therapeutic choices available. In the long run, the rise in medical tourism and investments in modernizing healthcare infrastructure across Asia Pacific's developing countries are projected to benefit the rare neurodegenerative disease treatment market. Long-term growth will be aided by advances in medical technology for the diagnosis and treatment of various ailments. Rare Neurological Disease Treatment Market- The incidence of rare diseases, the evolving trend of orphan drugs, and rising healthcare spending have all contributed to a significant increase in overall sales of rare neurological treatments during the previous decade. Furthermore, the rare neurological disease treatment market is expected to be the most attractive market among the rare disease treatment markets. Rapid advancements in healthcare, as well as major socioeconomic shifts that result in altered lifestyles, are allowing manufacturers to increase their footprint in the rare neurological disease treatment market. Intraoperative MRI Equipment Market- Intraoperative MRI equipment is becoming more popular around the world. Manufacturers of medical devices are working to improve the efficiency of intraoperative MRI equipment for operation localization. Physicians can now study images during a neurosurgical procedure rather than referring to prior and postoperative images thanks to this technology. New intraoperative MRI equipment on the market now allows for real-time viewing throughout all stages of brain surgery, which is expected to increase demand in the future years. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Source: Fact.MR